Creating patient-derived tumor models for head and neck cancer
Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
This study is trying to collect tumor samples from patients with head and neck cancer to create models that help test new treatments and understand how these tumors respond to them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT02572778 on ClinicalTrials.gov |
What this trial studies
This study aims to collect fresh tumor tissue from patients with primary or recurrent head and neck squamous cell carcinoma to establish patient-derived xenograft models. These models will be used to create a biobank representing various tumor subgroups, allowing for genetic and transcriptional profiling. The research will also evaluate the efficacy of new targeted therapies and biomarkers of drug sensitivity, as well as study resistance mechanisms in these tumors. The approach involves local biopsies to obtain the necessary tumor samples.
Who should consider this trial
Good fit: Ideal candidates include patients with primary or recurrent squamous cell carcinoma of the head and neck who can provide informed consent.
Not a fit: Patients with non-squamous cell carcinoma or those who are not eligible for biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatment options for patients with head and neck cancer.
How similar studies have performed: Other studies utilizing patient-derived xenografts have shown promise in cancer research, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent * Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available * Follow-up data should be available * Patients with recurrent disease are allowed * Written informed consent
Where this trial is running
Brussels
- Cliniques universitaires Saint-Luc — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Jean-Pascal Machiels, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Aline Gillain, MedSciences
- Email: aline.gillain@uclouvain.be
- Phone: 00322764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.